Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Reduced by Thematics Asset Management

Thematics Asset Management reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 18.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,836 shares of the medical research company's stock after selling 9,983 shares during the quarter. Thematics Asset Management's holdings in Thermo Fisher Scientific were worth $22,805,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of TMO. Howard Capital Management Group LLC raised its holdings in shares of Thermo Fisher Scientific by 0.5% in the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock valued at $33,759,000 after buying an additional 286 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Thermo Fisher Scientific by 22.1% in the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock valued at $771,876,000 after acquiring an additional 225,568 shares during the last quarter. M&T Bank Corp raised its holdings in Thermo Fisher Scientific by 4.2% during the third quarter. M&T Bank Corp now owns 113,347 shares of the medical research company's stock worth $70,113,000 after purchasing an additional 4,584 shares in the last quarter. Virtu Financial LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth $638,000. Finally, Anchor Investment Management LLC increased its position in Thermo Fisher Scientific by 1.7% in the 3rd quarter. Anchor Investment Management LLC now owns 11,366 shares of the medical research company's stock valued at $7,031,000 after acquiring an additional 195 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TMO. Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $680.00 to $580.00 and set an "overweight" rating for the company in a report on Thursday, April 17th. Raymond James reissued an "outperform" rating and set a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Scotiabank boosted their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research note on Monday, February 3rd. Finally, Royal Bank of Canada set a $693.00 price target on Thermo Fisher Scientific in a research report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $641.18.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company's stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares of the company's stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 over the last quarter. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 0.6 %

NYSE:TMO traded down $2.42 during mid-day trading on Wednesday, hitting $432.31. The company had a trading volume of 3,491,900 shares, compared to its average volume of 1,729,740. The firm has a market capitalization of $163.19 billion, a price-to-earnings ratio of 26.15, a PEG ratio of 2.99 and a beta of 0.86. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 1 year low of $409.85 and a 1 year high of $627.88. The business has a fifty day simple moving average of $493.38 and a 200-day simple moving average of $530.71.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a $0.43 dividend. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is presently 10.41%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.